| The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective A Griffiths, N Paracha, A Davies, N Branscombe, MR Cowie, M Sculpher Heart 100 (13), 1031-1036, 2014 | 74 | 2014 |
| Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients N Paracha, A Abdulla, KS MacGilchrist Health and quality of life outcomes 16, 1-30, 2018 | 61 | 2018 |
| Mixture cure models in oncology: a tutorial and practical guidance F Felizzi, N Paracha, J Pöhlmann, J Ray PharmacoEconomics-open 5, 143-155, 2021 | 42 | 2021 |
| Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic review N Paracha, PO Thuresson, SG Moreno, KS MacGilchrist Expert review of pharmacoeconomics & outcomes research 16 (5), 549-559, 2016 | 35 | 2016 |
| Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or … N Paracha, A Reyes, V Diéras, I Krop, X Pivot, A Urruticoechea Breast cancer research and treatment 180, 597-609, 2020 | 34 | 2020 |
| Analyzing health-related quality of life data to estimate parameters for cost-effectiveness models: an example using longitudinal EQ-5D data from the SHIFT randomized … A Griffiths, N Paracha, A Davies, N Branscombe, MR Cowie, M Sculpher Advances in therapy 34, 753-764, 2017 | 34 | 2017 |
| Episode pattern and healthcare utilisation in patients with seasonal allergic rhinitis R Pitman, N Paracha, C Parker, S Acaster, C Bachert, J Bousquet, D Price 31st Congress of the European Academy of Allergy and Clinical Immunology …, 2012 | 29 | 2012 |
| Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC) U Ondhia, HJ Conter, S Owen, A Zhou, J Nam, S Singh, A Abdulla, P Chu, ... Journal of medical economics 22 (7), 625-637, 2019 | 28 | 2019 |
| Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma B Woods, N Paracha, DA Scott, N Thatcher Lung Cancer 75 (2), 261-267, 2012 | 27 | 2012 |
| Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data … S Ali, N Paracha, S Cook, G Giovannoni, G Comi, K Rammohan, ... Clinical drug investigation 32, 15-27, 2012 | 19 | 2012 |
| Systematic literature review to assess the cost and resource use associated with spinal muscular atrophy management N Paracha, P Hudson, S Mitchell, CS Sutherland Pharmacoeconomics, 1-28, 2022 | 18 | 2022 |
| Systematic literature review to assess economic evaluations in spinal muscular atrophy (SMA) N Paracha, P Hudson, S Mitchell, CS Sutherland Pharmacoeconomics, 1-21, 2021 | 18 | 2021 |
| Indirect treatment comparison of larotrectinib versus entrectinib in treating patients with TRK gene fusion cancers J Garcia-Foncillas, C Bokemeyer, A Italiano, K Keating, N Paracha, ... Cancers 14 (7), 1793, 2022 | 16 | 2022 |
| Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France S Marine, R Stéphane, P Nicolas, F Felizzi, N Paracha, M Benjamin, ... Journal of Medical Economics 23 (5), 464-473, 2020 | 15 | 2020 |
| Comparison of alternative methods to assess the cost-effectiveness of tumor-agnostic therapies: a triangulation approach using larotrectinib as a case study A Briggs, B Wehler, JG Gaultney, A Upton, A Italiano, C Bokemeyer, ... Value in Health 25 (6), 1002-1009, 2022 | 13 | 2022 |
| Systematic literature review to identify utility values in patients with spinal muscular atrophy (SMA) and their caregivers CS Sutherland, P Hudson, S Mitchell, N Paracha Pharmacoeconomics, 1-29, 2022 | 11 | 2022 |
| Supporting biomarker-driven therapies in oncology: a genomic testing cost calculator A Stenzinger, B Cuffel, N Paracha, E Vail, J Garcia-Foncillas, C Goodman, ... The oncologist 28 (5), e242-e253, 2023 | 9 | 2023 |
| Preferences and utilities for treatment attributes in type 2 and non-ambulatory type 3 spinal muscular atrophy in the United Kingdom SH Lo, K Gorni, CS Sutherland, Y Martí, A Lloyd, N Paracha Pharmacoeconomics, 1-12, 2022 | 9 | 2022 |
| Survival outcomes of patients with tropomyosin receptor kinase fusion-positive cancer receiving larotrectinib versus standard of care: a matching-adjusted indirect comparison … C Bokemeyer, N Paracha, U Lassen, A Italiano, SD Sullivan, M Marian, ... JCO Precision Oncology 7, e2200436, 2023 | 7 | 2023 |
| Accounting for uncertainty in decision analytic models using rank preserving structural failure time modeling: application to parametric survival models I Bennett, N Paracha, K Abrams, J Ray Value in Health 21 (1), 105-109, 2018 | 6 | 2018 |
